FDA moves to ease path for biosimilars as Trump seeks to cut drug costs

Taking stock of the drug industry, from the lab to the medicine chest

October 29, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | FDA moves to ease path for biosimilars as Trump seeks to cut drug costs The FDA wants to make it quicker to approve biosimilars, part of President Trump's efforts to lower U.S. drug prices. By Daniel Payne Opinion: U.S. biomedical innovation must not go the way of semiconductors and shipbuilding A clear pattern has emerged of the U.S. rising as the star of manufacturing and innovating essential goods, only to hand the business to China. By Tim Scott Opinion: A 'devil's choice' on vaccines and pandemic preparedness Global vaccine expert Seth Berkley on what went right and wrong with Covid — and preparing for the next pandemic. By Torie Bosch Lexey Swall for STAT Scientists had to change more than 700 grant titles to receive NIH funding. Health disparities researchers fear what's next NIH denies having a banned words list but a new analysis finds hundreds of grant titles were changed to avoid terms like equity, disparity, and minority. By Anil Oza

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser